Corporate & Background
 Custom Manufacturing
 Business & Products
 Facilities & Strengths
R & D
Quality Unit
 Ethics & Values
 Regulatory Submissions
 Investors & Financials
 Locations & Contact
 Media Center
     Our Nutraceuticals website
      News & Events

 Divi's Labs earns an Income of Rs.366 crores in Q2 of FY12
  Divi's Labs earns a PBT of Rs. 130 crores for Q1 of FY12
  Divi's Labs PAT for Q4 grew by 36% to Rs.175 crores
  Divi's Labs earns an Income of Rs.313 crores for Q3 of FY11
  Divi's Labs earns an Income of Rs.265 crores in Q1
  Divi's Labs earns a PAT of Rs.129 crores for Q4
  Divi's Labs earns an Income of Rs.649 crores for 9M of FY10
  Divi's Labs earns an Income of Rs.445 crores in H1 of FY10
  Divi's Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus
  Divi's Labs PAT for 9 months
grows by 21% to Rs.309 crores
  Divi's Labs PAT for Q2 grows by
49% to Rs.135 crores
  Divi's Labs PAT for Q1 grows by
45% to Rs.94 crores
  Divi's Labs PAT for FY08 grows by 87% to Rs.348 crores
  Divi's Labs PAT for Q3 grows by 216% to Rs.99 crores
  Divi's Labs PAT for Q2 grows by 204% to Rs.91 crores
  Divi's Labs PAT for Q1 grows by 153% to Rs.65 crores
  Divi's Labs PAT for FY07
grows by 167% to Rs.186 crores
  Divi's Labs Q3 total income
 grows by 38% to Rs.152 crores
 Divis successful US-FDA inspection for Unit II
  Divi's Labs Q2 total income
 grows by 97% to Rs.165 crores.
  Divi's Labs Q1 total
 income grows by 142% at
 Rs.165 crores
  Divi's Laboratories earns a
 Net of Rs.19 crores
 on an Income of
 Rs.110 Crores in Q3
 Divis labs SEZs cleared
  Divis Laboratories earns a
 PBT of Rs.43 Crores in
 First-Half of FY06
  Divis Laboratories earns a
 total income of Rs.68
 Crores in Q1 of FY06
  Divis Laboratories earns a
 total income of Rs.365
 Crores in FY05
  Divis Laboratories earns a
 Net of Rs.105 Crores in Q3
  Divis Laboratories earns a
 PBT of Rs.45 Crores in
 First-Half of FY05
  Divis Laboratories earns a
 Net of Rs.14 Crores in Q1
R & D

The main aim of the Divis R&D Centers is to design, develop and optimize commercially viable synthetic processes for APIs and Intermediates of Generics and customer's discovery products.

Divis has four Research & Development facilities. The main R&D Center is at Hyderabad, working round the clock which was originally started as Divis Research Center (DRC) in Hyderabad and has a team of high caliber scientists.

Autoclaves and hydrogenators are available for conducting high temperature and high-pressure experimental reactions. The Centers have state-of-the-art instruments like automated multifunctional reaction systems , an analytical laboratory and a library with 24 hours internet access. Divis R&D has evaluated more than 500 product opportunities and developed processes for more than 200 products, out of which 80 are already at commercial scale.

Apart from the above, each plant has its own R&D center.

Besides the required infrastructure, the Hyderabad plant's R&D center has a Pilot Plant for scale-up studies, various materials of construction comprising 44 reactors of from 100 to 2000 Lt. capacity various materials of construction. All Four Research facilities are inspected and certified as per ISO 9000 standards.

Hyderabad plant R&D centre has the GMP Kilo lab having 5 all glass reaction units from 20 lts to 100 lts and all the necessary equipment to make API under GMP.

The third well equipped research facility of Divis at Visakhapatnam is primarily engaged in on process and commercial scale viability studies..

Chemical Hazard evaluation lab is attached to R&D at Hyderabad facility to conduct reaction calorimetry and is run by group of chemical Engineers and chemists.All the processes are evaluated and necessary recommendations are given to run the process commercially.

There is a pool of more than 250 scientists working in all the four research centers. Both DRC-Hyderabad and DRC-Vizag have been recognized by the Department of Science & Technology of Govt. of India, as industry research centers. The DRC-HYD centre is also recognized by a few universities for doctoral work.

Broad areas of engagement of the Research Centers:

Development of alternative routes of synthesis to achieve patent non- infringement.
Study and development of less hazardous and safer process, avoiding corrosive and harmful reagents, solvents, process conditions etc.
Development of environment friendly effluent and/or waste by products.
Attempts to recycle by products and achieve zero waste output.
Achieve higher quality product.
Optimizing production efficiency and economy of scale without sacrificing quality.

R&D Units also carry out Process Justification, Cleaning Procedures, Specification Development, Analytical Method Development, Rework Procedures, Validation Studies, Stability Studies and Investigations.

Focus areas of engagement of each Research Center:

DRC - Hyderabad

Contract Research and investigations/studies in new areas of chemistry like peptides, nucleotides, carbohydrates and Projects of some leading multi-national pharmaceutical companies.

DRC - Vizag
Development of patent non- infringing processes for APIs going off-patent in the near future.

R&D - Unit-1 AND Unit-2

Evaluation of technologies from customer or the company's research centers, completion of process justification, process optimization, scale-up, pilot studies and validation. R&D also gives process support and implements process improvements in the Plants. A few of the process improvements developed at Divis have also been implemented on client’s sites after maturation.

R&D is responsible for conducting the chemical hazard evaluation studies.

Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved     Web design london